Unlocking Immunotherapies for Solid Cancer Patients Immatics Corporate Presentation, November 2021 © Immatics. Not for further reproduction or distribution. Forward-Looking Statements This presentation ("Presentation") is provided by Immatics N.V. ("Immatics" or the "Company") for informational purposes only. The information contained herein does not purport to be all-inclusive and Immatics nor any of its affiliates nor any of its or their control persons, officers, directors, employees or representatives m ...

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents For the fiscal year ended December 31, 2020 OR (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Securities for which there is a reporting obligation pursuant to Section 15( ...

Company Overview - Immatics is building a global leadership position in TCR-based immunotherapies, leveraging proprietary platforms for target and T cell receptor discovery[3] - The company has validated its platforms through strategic collaborations with oncology-focused global leaders, including Amgen, Genmab, BMS, GSK, and MD Anderson Cancer Center[3] - Immatics had approximately $320 million in cash on its balance sheet after its NASDAQ debut, providing a cash runway of 3+ years[4] Pipeline Development - Immatics is advancing a proprietary pipeline of Adoptive Cell Therapies (ACT) and TCR Bispecifics, with four ACT programs in clinical development covering a broad range of solid cancers[3] - Two TCR Bispecifics programs with off-the-shelf availability are in advanced preclinical development[3] - The company's lead candidate for the IMA402 program is expected by YE 2020[7] - IND filing for IMA204 is planned for 2021[7] - IND filing for IMA401 is on track for YE 2021[7] - IMA301 program is on track for an IND filing in 2022[7] Technology and Targets - Immatics has prioritized over 200 pHLA targets using its XPRESIDENT® technology platform[9, 10, 16, 41] - The company's ACTengine® targets, such as MAGEA4/A8 (IMA201), MAGEA1 (IMA202), PRAME (IMA203), and COL6A3 exon 6 (IMA204), show high pHLA copy numbers per cell, ranging from 50-1,000[22, 26] Clinical Trial Updates - Initial data from IMA201, IMA202, and IMA203 ACTengine® trials showed very high frequencies of persisting circulating target-specific T cells, up to 45%, at the lowest infused dose[23] - Topline data for the multi-target pilot study IMA101 is planned to be presented at a scientific conference in 4Q 2020[63]